대한골관절종양학회지 (The Journal of the Korean bone and joint tumor society)

  • 제18권2호
  • /
  • Pages.66-71
  • /
  • 2012
  • /
  • 1226-4962(pISSN)
  • /
  • 2233-9841(eISSN)
대한근골격종양학회 (The Korean Musculoskeletal Tumor Society)
권호 표지
DOI QR코드

DOI QR Code

천골에 발생한 척색종의 치료결과

Oncologic Outcome of Sacral Chordoma

  • Cho, Sang-Hyun (Department of Orthopedic Surgery, Dongnam Inst. of Radiological & Medial Sciences) ;
  • Lee, Soo Yong (Department of Orthopedic Surgery, Korea Cancer Center Hospital) ;
  • Jeon, Dae-Geun (Department of Orthopedic Surgery, Korea Cancer Center Hospital) ;
  • Song, Won-Seok (Department of Orthopedic Surgery, Korea Cancer Center Hospital) ;
  • Kong, Chang-Bae (Department of Orthopedic Surgery, Korea Cancer Center Hospital) ;
  • Lee, Jung-Dong (Department of Orthopedic Surgery, Korea Cancer Center Hospital) ;
  • Cho, Wan-Hyeong (Department of Orthopedic Surgery, Korea Cancer Center Hospital)
  • 투고 : 2012.10.23
  • 심사 : 2012.11.20
  • 발행 : 2012.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 천골에 발생한 척색종의 치료결과 분석을 통해 생존율 및 종양의 국소조절과 연관된 예후인자에 대하여 알아보고자 하였다. 대상 및 방법: 1990년 1월부터 2010년 2월까지 본원에서 치료받은 19예를 대상으로 하였다. 평균연령은 56세였으며 남자9예, 여자 10예였다. 15명의 환자에서 후방접근법을 이용한 절제술을 시행하였으며 4명의 환자는 방사선 치료만을 시행하였다. 종양의 위치가 S3 보다 근위부를 침범한 경우가 6예였으며 이중 4예에서 방사선 치료만을 시행하였다. 광범위 절제 6예, 변연부 절제 8예, 병소내 절제 1예였다. 평균 추시 기간은 63개월(25-144개월)이었다. 결과: 5년 무병 생존율 및 전체 생존율은 각각 34.7%, 79.7%였다. 재발은 9예, 원격전이는 7예에서 발생하였다. 생존율에 관계된 예후 인자는 종양의 제3천추 상방 침범유무(p=0.033), 종양의 크기(p=0.032)였다. 수술 후 합병증으로 배뇨 및 배변 장애가 발생한 경우가 9예였으며 이중 2예에서는 자가도뇨 시행이 필요하거나 중증의 요실금이 발생하였다. 결론: 종양의 절제 가능성 여부와 더불어 전반적인 환자상태와 수술 후 발생 가능한 합병증을 고려한 치료방법의 선택이 생존율과 함께 삶의 질을 높일 수 있는 방법으로 생각된다.

Purpose: We analyzed treatment result to examine the outcome for patients with sacral chordoma and to determine relevant prognostic factors. Materials and Methods: We retrospectively reviewed 19 patients with sacral chordoma seen at out institution between 1990 and 2010. There were 9 men and 10 women with mean age of 56 years. The average follow up was 63 months (range, 25-144 months). 15 patient received surgical treatment, six of these patient had wide, eight had marginal, one had intralesional margin and 4 patient treated with Radiation therapy only. Results: The disease free and overall survival rate for all 19 patients was 34.7% and 79.7% at 5-years, respectively. Statistical analysis using the log-rank test revealed no significant difference between the surgery and radiation therapy groups in overall survival (p=0.54). Nine of 19 patients had local recurrence at a median of 2.5 years postoperatively. Seven of these 9 patients had distant metastasis at a median of 4.5 years postoperatively. Among the variables, tumor size (p=0.033) and tumor involvement of above S3 (p=0.032) were independent prognostic factor for overall survival. Nine of 15 patients who received surgical treatment had postoperative complication such as voiding difficulty and incontinence. Conclusion: Careful consideration of the patient general condition and predictable complication of the treatment might be the best way to improve patient's survival and quality of life.

키워드

참고문헌

  1. Hanna SA, Aston WJ, Briggs TW, Cannon SR, Saifuddin A. Sacral chordoma: can local recurrence after sacrectomy be predicted? Clin Orthop Relat Res. 2008;466:2217-23.
  2. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control. 2001;12:1-11.
  3. Ferraresi V, Nuzzo C, Zoccali C, et al. Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. BMC Cancer. 2010;10:22.
  4. Nishida Y, Kamada T, Imai R, et al. Clinical outcome of sacral chordoma with carbon ion radiotherapy compared with surgery. Int J Radiat Oncol Biol Phys. 2011;79:110-6.
  5. Mirra JM, Della Rocca C, Nelson SD, Mertens F. Chordoma. In: Fletcher CD, Unni K, Mertens F, ed. Pathology and genetics of tumours of soft tissue and bone. Lyon, France: IARC Press; 2002. 316-7.
  6. Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012;13:e69-76.
  7. Catton C, O'Sullivan B, Bell R, et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol. 1996;41:67-72.
  8. York JE, Kaczaraj A, Abi-Said D, et al. Sacral chordoma: 40- year experience at a major cancer center. Neurosurgery. 1999;44:74-9.
  9. Samson IR, Springfield DS, Suit HD, Mankin HJ. Operative treatment of sacrococcygeal chordoma. A review of twentyone cases. J Bone Joint Surg Am. 1993;75:1476-84.
  10. Wuisman P, Lieshout O, Sugihara S, van Dijk M. Total sacrectomy and reconstruction: oncologic and functional outcome. Clin Orthop Relat Res. 2000;(381):192-203.
  11. Baratti D, Gronchi A, Pennacchioli E, et al. Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol. 2003;10:291-6.
  12. Hulen CA, Temple HT, Fox WP, Sama AA, Green BA, Eismont FJ. Oncologic and functional outcome following sacrectomy for sacral chordoma. J Bone Joint Surg Am. 2006;88:1532-9.
  13. Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH. Operative management of sacral chordoma. J Bone Joint Surg Am. 2005;87:2211-6.
  14. Kaiser TE, Pritchard DJ, Unni KK. Clinicopathologic study of sacrococcygeal chordoma. Cancer. 1984;53:2574-8.
  15. Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom JM. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000;88:2122-34.
  16. Gunterberg B, Norlén L, Stener B, Sundin T. Neurourologic evaluation after resection of the sacrum. Invest Urol. 1975;13:183-8.
  17. Gunterberg B, Kewenter J, Petersén I, Stener B. Anorectal function after major resections of the sacrum with bilateral or unilateral sacrifice of sacral nerves. Br J Surg. 1976;63:546-54.
  18. Zabel-du Bois A, Nikoghosyan A, Schwahofer A, et al. Intensity modulated radiotherapy in the management of sacral chordoma in primary versus recurrent disease. Radiother Oncol. 2010;97:408-12.
  19. Cheng EY, Ozerdemoglu RA, Transfeldt EE, Thompson RC Jr. Lumbosacral chordoma. Prognostic factors and treatment. Spine (Phila Pa 1976). 1999;24:1639-45.
  20. Stacchiotti S, Casali PG, Lo Vullo S, et al. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol. 2010;17:211-9.
  21. Stener B, Gunterberg B. High amputation of the sacrum for extirpation of tumors. Principles and technique. Spine (Phila Pa 1976). 1978;3:351-66.
  22. Yonemoto T, Tatezaki S, Takenouchi T, Ishii T, Satoh T, Moriya H. The surgical management of sacrococcygeal chordoma. Cancer. 1999;85:878-83.